Business Wire

Aqara Expands Security Camera Portfolio with First Doorbell Camera Hub

10.7.2025 09:00:00 CEST | Business Wire | Press Release

Share

Aqara, a global leader and pioneer in IoT, today announced the global availability of its next-generation video doorbell, the Doorbell Camera Hub G410. This 2K doorbell camera features enhanced image quality, a built-in presence sensor, on-device facial recognition, and seamless smart home integration. It also functions as a multi-protocol Matter hub, offering users a versatile solution for connecting their indoor and outdoor smart devices.

Equipped with dual-band Wi-Fi (2.4GHz/5GHz), Thread, Zigbee, and Bluetooth connectivity, the Doorbell Camera Hub G410 is designed to be the cornerstone of a smart home. As a Matter Controller, Thread Border Router, and Aqara Zigbee hub, it not only connects an assortment of Aqara devices but also supports more than 50 types of third-party Matter-compatible devices. These include locks, sensors, switches, lights, and even newer connected products like robovacs, home appliances, and EV chargers.

The G410 captures every detail at the doorstep with its 2K lens, f/1.8 aperture, and 175° wide-angle field of view. It also packs a millimeter-wave (mmWave) sensor for more accurate presence detection while minimizing false alerts. Its on-device facial recognition capability can identify visitors and trigger notifications or automations, all without requiring a subscription. Additionally, with the new Advanced Matter Bridging feature, users can bridge facial recognition as an automation trigger to third-party Matter platforms such as Home Assistant, maximizing the doorbell’s AI capability.

The Doorbell Camera Hub G410 can be seamlessly integrated into users’ existing smart home setups. It works with Apple Home and supports HomeKit Secure Video1, making it the ideal choice for iOS users, especially those seeking a battery-operated doorbell. It also streams to Alexa-, Google Home-, and SmartThings-compatible smart displays. Supporting RTSP protocol2, the G410 can stream to third-party clients like Home Assistant over the local network and supports NVR software such as Frigate and Blue Iris.

Designed for flexibility, the G410 doorbell offers both cloud and local storage options. Storage on the Aqara cloud is end-to-end encrypted for enhanced privacy protection, with users receiving 1-day free storage for 6 months or 90-day storage with a HomeGuardian subscription. iCloud storage is also available with the appropriate iCloud subscription. For local storage, a microSD card of up to 512 GB is supported3, and it is housed in the chime to prevent tampering from the outside. Furthermore, users can back up their videos to a local NAS system for expanded storage capacity and centralized access.

The G410 can be used with or without a power cable, offering convenience and flexibility. For uninterrupted use and continuous 24/7 recording, users can hardwire the doorbell to a low-voltage AC/DC power supply4. Alternatively, it can run on six AA batteries, offering up to five months of battery life5.

The Aqara Doorbell Camera Hub G410 is now available for purchase through Aqara’s official website, authorized retailers, and major e-commerce platforms such as Amazon (Canada, France, Germany, Italy, Netherlands, Poland, Spain, UK, US).

For more information on the new doorbell camera, please visit the Aqara website.

  1. HomeKit Secure Video requires an iCloud subscription and an Apple home hub, with a resolution limitation of 1200p.
  2. The RTSP support is only available when the doorbell is hardwired to a low voltage power supply.
  3. The microSD card is not included.
  4. 24/7 recording requires a microSD card and a constant power supply via a cable.
  5. The 5-month battery life is based on the assumption of 10 device wake-ups per day. Actual battery life may vary depending on the particular use case and environment, as frequent activation reduces battery life.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250710994716/en/

Contacts

For Media Inquiries:
media@aqara.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye